Sonim enters $17.5M subscription agreement with AJP; Peter Liu appointed CEO

DNA X, Inc.

AJP to buy 20.8M shares at $0.84/share for $17.5M; post-transaction AJP owns ~52%.
Peter Liu appointed CEO effective April 14, 2022; he is part of AJP investment group.
First closing of $12.5M for 14.9M shares requires stockholder approval; second closing of $5M later.
Board reconstituted with AJP designees; Robert Tirva to resign at first closing with $1M severance.
Strategy shift: expand into semi-rugged and industrial 5G markets using ODM relationships.

item 1.01 item 3.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Robert Tirva

President, Chief Financial Officer and Chief Operating Officer

SONM · DNA X, Inc.

Filed: April 14, 2022, 7:59 PM ET

On April 13, 2022, the Compensation Committee of the Board of Directors of the Company approved a letter agreement with Robert Tirva, the Company’s President, Chief Financial Officer and Chief Operating Officer. The agreement provides that Mr. Tirva’s employment with the Company will terminate on, and subject to, the First Closing and that upon such termination, Mr. Tirva would be entitled to receive

Appointed

Peter Liu

Chief Executive Officer

SONM · DNA X, Inc.

Effective: 2022-04-13
Filed: April 14, 2022, 7:59 PM ET

on April 13, 2022, the board of directors of Sonim appointed Peter Liu as Chief Executive Officer of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Robert Tirva was terminated as President, Chief Financial Officer and Chief Operating Officer at DNA X, Inc..

Action: terminated
Role: President, Chief Financial Officer and Chief Operating Officer

Exact text from the filing

On April 13, 2022, the Compensation Committee of the Board of Directors of the Company approved a letter agreement with Robert Tirva, the Company’s President, Chief Financial Officer and Chief Operating Officer. The agreement provides that Mr. Tirva’s employment with the Company will terminate on, and subject to, the First Closing and that upon such termination, Mr. Tirva would be entitled to receive

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Liu was appointed as Chief Executive Officer at DNA X, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

on April 13, 2022, the board of directors of Sonim appointed Peter Liu as Chief Executive Officer of the Company

View on SEC.gov

DNA X, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-104993

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.